Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Roivant Sciences (ROIV) Equity Average (2020 - 2025)

Roivant Sciences' Equity Average history spans 6 years, with the latest figure at $4.5 billion for Q4 2025.

  • For Q4 2025, Equity Average fell 18.36% year-over-year to $4.5 billion; the TTM value through Dec 2025 reached $4.5 billion, down 18.36%, while the annual FY2025 figure was $5.1 billion, 21.56% down from the prior year.
  • Equity Average reached $4.5 billion in Q4 2025 per ROIV's latest filing, down from $4.8 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $6.5 billion in Q1 2024 to a low of $1.3 billion in Q3 2023.
  • Average Equity Average over 5 years is $3.4 billion, with a median of $2.3 billion recorded in 2021.
  • Peak YoY movement for Equity Average: crashed 37.09% in 2022, then surged 331.44% in 2024.
  • A 5-year view of Equity Average shows it stood at $2.3 billion in 2021, then plummeted by 37.09% to $1.5 billion in 2022, then soared by 168.94% to $4.0 billion in 2023, then surged by 40.53% to $5.6 billion in 2024, then decreased by 18.36% to $4.5 billion in 2025.
  • Per Business Quant, the three most recent readings for ROIV's Equity Average are $4.5 billion (Q4 2025), $4.8 billion (Q3 2025), and $4.8 billion (Q2 2025).